Iovance Biotherapeutics, Inc.
825 Industrial Rd
Suite 400
San Carlos
California
94070
United States
Website: http://www.iovance.com/
276 articles with Iovance Biotherapeutics, Inc.
-
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
3/24/2023
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced it has completed its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for lifileucel.
-
Iovance Biotherapeutics to Present at Upcoming Conferences - March 01, 2023
3/1/2023
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following conferences.
-
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
2/28/2023
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported fourth quarter and full year 2022 financial results and corporate updates.
-
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
2/21/2023
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023.
-
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
1/23/2023
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today provided corporate, clinical, and regulatory updates.
-
Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million
1/23/2023
Clinigen Limited (‘Clinigen’) (‘the Company’), the global pharmaceutical services company, has entered into an agreement to divest Proleukin® (interleukin-2 (aldesleukin)), to Iovance Biotherapeutics, Inc.
-
Iovance Biotherapeutics to Present at Upcoming Conferences - November 30, 2022
11/30/2022
Iovance Biotherapeutics, Inc. today announced that senior leadership plans to present at the following conferences: Piper Sandler 34th Annual Healthcare Conference Fireside Chat: November 30, 2022 at 10:30 a.m. ET / 7:30 a.m. PT.
-
Iovance Biotherapeutics announced the FDA's Biologics License Application for lifileucel will likely be completed in Q1 of 2023, a short delay after the agency requested additional data.
-
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma BLA Submission Ongoing with U.S. Food and Drug Administration
11/18/2022
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced that its ongoing rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for lifileucel is expected to be completed in the first quarter of 2023.
-
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/7/2022
Iovance Biotherapeutics, Inc.\ announced the publication of abstracts reporting clinical data and a trial in progress for Iovance tumor-infiltrating lymphocyte cell therapies for the upcoming Society for Immunotherapy of Cancer Annual Meeting, November 8-12, 2022, in Boston, MA and virtually.
-
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates
11/3/2022
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported third quarter and year-to-date 2022 financial results and corporate updates.
-
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022
10/24/2022
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter financial results on Thursday, November 3, 2022.
-
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
10/10/2022
Iovance Biotherapeutics, Inc. announced that the first patient was dosed, and completed the safety observation period, in the IOV-GM1-201 trial of Iovance’s genetically modified, PD-1 inactivated TIL therapy, IOV-4001.
-
Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
10/5/2022
Iovance Biotherapeutics, Inc. today announced oral and poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) cell therapies at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting in Boston, Massachusetts, November 8-12, 2022.
-
Iovance Biotherapeutics to Present Posters at ESMO 2022
9/6/2022
Iovance Biotherapeutics, Inc. announced the publication of abstracts reporting clinical data and trial design for tumor infiltrating lymphocyte cell therapies at the European Society for Medical Oncology Congress 2022 in Paris, France, September 9 – 13, 2022.
-
Iovance Biotherapeutics to Present at Upcoming Conferences in September 2022
9/6/2022
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following conferences in September.
-
The FDA is keeping busy as summer winds down, with approvals, Orphan Drug Designations and other actions. Here’s what the agency has been up to this week.
-
Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
8/25/2022
Iovance Biotherapeutics, Inc. today announced that it has initiated a rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for lifileucel.
-
Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates
8/4/2022
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported second quarter and first half 2022 financial results and corporate updates.
-
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - July 22, 2022
7/22/2022
Iovance Biotherapeutics, Inc. announced that on July 21, 2022, the Company approved the grant of inducement stock options covering an aggregate of 39,400 shares of Iovance’s common stock to 15 new non-executive employees.